Valuation: EyePoint, Inc.

Market Cap 1.02B 898M 835M 766M 1.44B 98.42B 1.46B 9.91B 3.87B 48.39B 3.84B 3.75B 167B P/E 2026 *
-3.42x
P/E 2027 * -4.1x
Enterprise Value 728M 639M 594M 545M 1.02B 70.08B 1.04B 7.06B 2.76B 34.45B 2.73B 2.67B 119B EV / Sales 2026 *
415x
EV / Sales 2027 * 26.2x
Free-Float
96.32%
Yield 2026 *
-
Yield 2027 * -
1 day-2.25%
1 week-8.35%
Current month-14.76%
1 month-10.76%
3 months-11.47%
6 months-21.10%
Current year-33.28%
1 week 12.06
Extreme 12.06
13.23
1 month 12.06
Extreme 12.06
15.92
Current year 11.3
Extreme 11.295
18.87
1 year 9.4
Extreme 9.4
19.11
3 years 3.91
Extreme 3.91
30.99
5 years 2.19
Extreme 2.19
30.99
10 years 2.19
Extreme 2.19
42.5
Manager TitleAgeSince
Chief Executive Officer 67 10/07/2023
Director of Finance/CFO 61 14/11/2019
Chief Tech/Sci/R&D Officer 43 04/03/2024
Director TitleAgeSince
Director/Board Member 67 10/07/2023
Chairman 77 10/09/2018
Director/Board Member 73 25/10/2018
Date Insider Type Main position Quantity % Market Cap.
10/7/26 Fiscal year

Chief Executive Officer

41,393 0.0494%
30/6/26 Fiscal year

Chief Technology Officer

14,625 0.0174%
25/5/26 Fiscal year

Chief Financial Officer

18,627 0.0222%
Change 5-day change 1-year change 3-year change Capi.($)
-2.25%-8.35%+16.32%+19.39% 1.02B
+0.86%+1.43%+47.17%+163.68% 1,067B
+1.59%+4.09%+56.51%+52.50% 635B
+0.95%+1.91%+36.30%+82.78% 458B
+0.89%+7.99%+37.45%+31.47% 347B
+0.80%+3.92%+37.05%+40.96% 295B
+1.23%+3.67%+18.94%+19.94% 262B
+1.48%-0.96%-28.00%-38.96% 216B
+1.22%+2.66%+22.66%+59.87% 203B
-1.18%-3.70%+11.28%+67.52% 161B
Average +0.56%+0.36%+25.57%+49.92% 364.45B
Weighted average by Cap. +0.99%+1.95%+36.25%+79.21%

Financials

2026 *2027 *
Net sales 1.75M 1.54M 1.43M 1.31M 2.47M 169M 2.5M 16.99M 6.64M 82.93M 6.58M 6.43M 287M 32.76M 28.77M 26.76M 24.55M 46.13M 3.15B 46.84M 318M 124M 1.55B 123M 120M 5.36B
Net income -316M -278M -258M -237M -445M -30.45B -452M -3.07B -1.2B -14.97B -1.19B -1.16B -51.75B -289M -254M -236M -217M -407M -27.85B -414M -2.8B -1.1B -13.69B -1.09B -1.06B -47.33B
Net Debt -294M -259M -240M -221M -415M -28.34B -421M -2.85B -1.12B -13.94B -1.1B -1.08B -48.18B -164M -144M -134M -123M -230M -15.76B -234M -1.59B -620M -7.75B -614M -601M -26.78B
Logo EyePoint, Inc.
EyePoint, Inc., formerly EyePoint Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The Company’s lead product candidate, DURAVYU, is an investigational-sustained delivery treatment for serious retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor, with bioerodible Durasert E technology. Vorolanib features a novel multi-mechanism of action as it targets both vascular endothelial growth factor (VEGF)-mediated vascular permeability and IL-6 mediated inflammation through inhibition of all VEGF receptors and pro-inflammatory IL-6/JAK1 signaling. DURAVYU is in Phase III pivotal trials for wet age-related macular degeneration. DURAVYU is also being advanced for the treatment of diabetic macular edema (DME) with the first patient dosing in Phase III trials.
Employees
214
Date Price Change Volume
24/07/26 USD 12.19 -2.25% 1,468,697
23/07/26 USD 12.47 -1.50% 1,284,723
22/07/26 USD 12.66 -2.99% 1,063,990
21/07/26 USD 13.05 +3.08% 1,585,308
20/07/26 USD 12.66 -4.81% 1,099,731
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
12.19USD
Average target price
40.29USD
Spread / Average Target
+230.48%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. EYPT Stock